Annual CFF
$17.81 M
-$437.35 M-96.09%
31 December 2023
Summary:
Intra-Cellular Therapies annual cash flow from financing activities is currently $17.81 million, with the most recent change of -$437.35 million (-96.09%) on 31 December 2023. During the last 3 years, it has fallen by -$646.37 million (-97.32%). ITCI annual CFF is now -97.32% below its all-time high of $664.18 million, reached on 31 December 2020.ITCI Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$6.73 M
-$538.45 M-98.76%
30 September 2024
Summary:
Intra-Cellular Therapies quarterly cash flow from financing activities is currently $6.73 million, with the most recent change of -$538.45 million (-98.76%) on 30 September 2024. Over the past year, it has increased by +$4.15 million (+160.91%). ITCI quarterly CFF is now -98.76% below its all-time high of $545.18 million, reached on 30 June 2024.ITCI Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$564.91 M
+$4.15 M+0.74%
30 September 2024
Summary:
Intra-Cellular Therapies TTM cash flow from financing activities is currently $564.91 million, with the most recent change of +$4.15 million (+0.74%) on 30 September 2024. Over the past year, it has increased by +$547.91 million (+3224.35%). ITCI TTM CFF is now -14.95% below its all-time high of $664.18 million, reached on 31 December 2020.ITCI TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ITCI Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -96.1% | +160.9% | +3224.3% |
| 3 y3 years | -97.3% | +1039.4% | +7702.1% |
| 5 y5 years | +2499.2% | +4318.6% | +10000.0% |
ITCI Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -97.3% | +54.6% | -98.8% | +1039.4% | at high | +7702.1% |
| 5 y | 5 years | -97.3% | +2499.2% | -98.8% | +4318.6% | -14.9% | >+9999.0% |
| alltime | all time | -97.3% | +3628.3% | -98.8% | +105.4% | -14.9% | +552.9% |
Intra-Cellular Therapies Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $6.73 M(-98.8%) | $564.91 M(+0.7%) |
| June 2024 | - | $545.18 M(+5357.8%) | $560.75 M(+2221.1%) |
| Mar 2024 | - | $9.99 M(+232.5%) | $24.16 M(+35.6%) |
| Dec 2023 | $17.81 M(-96.1%) | $3.00 M(+16.4%) | $17.81 M(+4.8%) |
| Sept 2023 | - | $2.58 M(-69.9%) | $16.99 M(-15.3%) |
| June 2023 | - | $8.59 M(+135.9%) | $20.07 M(+18.1%) |
| Mar 2023 | - | $3.64 M(+66.4%) | $16.98 M(-96.3%) |
| Dec 2022 | $455.16 M(+3851.4%) | $2.19 M(-61.3%) | $455.16 M(-1.2%) |
| Sept 2022 | - | $5.65 M(+2.7%) | $460.89 M(+1.1%) |
| June 2022 | - | $5.50 M(-98.8%) | $455.82 M(+0.9%) |
| Mar 2022 | - | $441.81 M(+5482.7%) | $451.90 M(+3823.1%) |
| Dec 2021 | $11.52 M(-98.3%) | $7.91 M(+1239.1%) | $11.52 M(+59.1%) |
| Sept 2021 | - | $591.00 K(-62.6%) | $7.24 M(-98.1%) |
| June 2021 | - | $1.58 M(+10.5%) | $385.14 M(-0.7%) |
| Mar 2021 | - | $1.43 M(-60.6%) | $388.04 M(-41.6%) |
| Dec 2020 | $664.18 M(>+9900.0%) | $3.64 M(-99.0%) | $664.18 M(+0.1%) |
| Sept 2020 | - | $378.49 M(+8348.9%) | $663.33 M(+132.8%) |
| June 2020 | - | $4.48 M(-98.4%) | $284.99 M(+1.5%) |
| Mar 2020 | - | $277.57 M(+9838.7%) | $280.77 M(+8577.6%) |
| Dec 2019 | $3.24 M(+372.2%) | $2.79 M(+1732.5%) | $3.24 M(+414.6%) |
| Sept 2019 | - | $152.40 K(-41.2%) | $628.70 K(-0.5%) |
| June 2019 | - | $259.20 K(+730.8%) | $631.70 K(+66.9%) |
| Mar 2019 | - | $31.20 K(-83.2%) | $378.60 K(-44.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | $685.20 K(-99.6%) | $185.90 K(+19.6%) | $685.20 K(-99.6%) |
| Sept 2018 | - | $155.40 K(+2447.5%) | $162.63 M(+0.1%) |
| June 2018 | - | $6100.00(-98.2%) | $162.47 M(-0.0%) |
| Mar 2018 | - | $337.80 K(-99.8%) | $162.47 M(+0.1%) |
| Dec 2017 | $162.36 M(>+9900.0%) | $162.13 M(>+9900.0%) | $162.36 M(-230.2%) |
| Sept 2017 | - | $0.00(-100.0%) | -$124.74 M(<-9900.0%) |
| June 2017 | - | $6600.00(-97.1%) | $360.50 K(-33.0%) |
| Mar 2017 | - | $224.20 K(-100.2%) | $538.30 K(+12.7%) |
| Dec 2016 | $477.70 K(-99.9%) | -$124.97 M(-199.9%) | $477.80 K(-99.6%) |
| Sept 2016 | - | $125.10 M(>+9900.0%) | $125.77 M(-61.7%) |
| June 2016 | - | $184.40 K(+12.6%) | $328.18 M(+0.0%) |
| Mar 2016 | - | $163.70 K(-49.5%) | $328.17 M(-27.1%) |
| Dec 2015 | $449.89 M(+288.8%) | $324.40 K(-99.9%) | $449.89 M(+0.1%) |
| Sept 2015 | - | $327.50 M(>+9900.0%) | $449.63 M(+268.1%) |
| June 2015 | - | $174.00 K(-99.9%) | $122.16 M(+0.0%) |
| Mar 2015 | - | $121.89 M(>+9900.0%) | $122.15 M(+5.6%) |
| Dec 2014 | $115.72 M(+184.8%) | $63.90 K(+120.3%) | $115.72 M(+0.1%) |
| Sept 2014 | - | $29.00 K(-82.9%) | $115.65 M(+0.0%) |
| June 2014 | - | $169.40 K(-99.9%) | $115.62 M(+0.1%) |
| Mar 2014 | - | $115.45 M(>+9900.0%) | $115.46 M(>+9900.0%) |
| Dec 2013 | $40.63 M(+167.4%) | - | - |
| June 2013 | - | $5900.00 | $5900.00 |
| Dec 2012 | $15.19 M | - | - |
FAQ
- What is Intra-Cellular Therapies annual cash flow from financing activities?
- What is the all time high annual CFF for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies annual CFF year-on-year change?
- What is Intra-Cellular Therapies quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies quarterly CFF year-on-year change?
- What is Intra-Cellular Therapies TTM cash flow from financing activities?
- What is the all time high TTM CFF for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies TTM CFF year-on-year change?
What is Intra-Cellular Therapies annual cash flow from financing activities?
The current annual CFF of ITCI is $17.81 M
What is the all time high annual CFF for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high annual cash flow from financing activities is $664.18 M
What is Intra-Cellular Therapies annual CFF year-on-year change?
Over the past year, ITCI annual cash flow from financing activities has changed by -$437.35 M (-96.09%)
What is Intra-Cellular Therapies quarterly cash flow from financing activities?
The current quarterly CFF of ITCI is $6.73 M
What is the all time high quarterly CFF for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high quarterly cash flow from financing activities is $545.18 M
What is Intra-Cellular Therapies quarterly CFF year-on-year change?
Over the past year, ITCI quarterly cash flow from financing activities has changed by +$4.15 M (+160.91%)
What is Intra-Cellular Therapies TTM cash flow from financing activities?
The current TTM CFF of ITCI is $564.91 M
What is the all time high TTM CFF for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high TTM cash flow from financing activities is $664.18 M
What is Intra-Cellular Therapies TTM CFF year-on-year change?
Over the past year, ITCI TTM cash flow from financing activities has changed by +$547.91 M (+3224.35%)